Heart Transplant

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

XVIVO
XVIVOSweden - Mölndal
1 program
Non-Ischemic Heart PreservationN/A1 trial
Active Trials
NCT06895070RecruitingEst. May 2031
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
transplantN/A1 trial
Active Trials
NCT02182986CompletedEst. May 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
XVIVONon-Ischemic Heart Preservation
Allergy Therapeuticstransplant

Clinical Trials (2)

NCT06895070XVIVONon-Ischemic Heart Preservation

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

Start: Jul 2025Est. completion: May 2031
N/ARecruiting

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Start: Aug 2014Est. completion: May 2019
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
2 companies competing in this space